Teva On Track To Hit Targets With Truxima

Targeting New Patients With US Rituximab Biosimilar

 
• By David Wallace
  
Teva_Magnified
Teva has forecast sales of $17.2bn-$17.4bn in 2019 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business